The contractor shall provide project management services for all required bioequivalence review activities; for all issues relevant to the workflow management of ogdp and the development and…
Ended Awarded Last action
- Contract number
- 75F40119F19063
- Awardee
-
Brillient Corporation UEI MMAVC7UGLJ78
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $7,592,324
Award facts
- Contract value 100% obligated
- $7,592,323.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Labor Hours
- Place of performance
- Reston, VA 20190, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$335,419 | |
| Supplemental Agreement for work within scope | $333,162 | |
| Supplemental Agreement for work within scope | $359,413 | |
| Supplemental Agreement for work within scope | $720,444 | |
| Supplemental Agreement for work within scope | $1,687,964 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $1,656,549 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,600,023 | |
| Original award | $1,570,188 |
About this award
This is a Blanket Purchase Agreement (BPA) call contract awarded by the Food and Drug Administration (FDA), a civilian agency, to Brillient Corporation, a minority-owned small business. The contract is for $7,592,323.80 and will provide project management services to support the FDA's Office of Generic Drug Policy's workflow management, data and information, and regulatory science research program. The contract falls under the General Services Administration's Professional Services Schedule (PSS) and does not have a set-aside designation. Brillient Corporation is the prime contractor and will provide these services through August 2024.
Description
The contractor shall provide project management services for all required bioequivalence review activities; for all issues relevant to the workflow management of ogdp and the development and documentation of policies and processes; issues relevant to the cder informatics platform related data and information; and support relating to the gdufa regulatory science research program.
Quick answers
Who was awarded contract 75F40119F19063?
75F40119F19063 was awarded to Brillient Corporation by Food and Drug Administration (Department of Health and Human Services) on June 21, 2019.
How much is contract 75F40119F19063 worth?
The government has obligated $7,592,324 on 75F40119F19063.
Is contract 75F40119F19063 an order under another contract?
Yes. 75F40119F19063 is a BPA call under GS00F012BA-HHSF223201810005B, a blanket purchase agreement, on The Professional Services Schedule (PSS).
Was contract 75F40119F19063 competed?
The extent of competition for 75F40119F19063 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award